PAS
INMB icon

Point72 Asia (Singapore)’s INmune Bio INMB Stock Holding History

Point72 Asia (Singapore)’s Portfolio INMB Stock Details INMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-13,438
Closed -$158K – 1250
2024
Q1 		$158K Buy
+13,438
New +$162K 0.04% 510

Other funds holding INMB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
PP
Praetorian PR Rincon, Puerto Rico $275M AUM 84.95% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RJFSA
Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $810M AUM 30.2% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Point72 Asia (Singapore)'s INMB Position: Q2 2024 in Review

Point72 Asia (Singapore) sold out of INmune Bio (INMB) in Q2 2024, closing a stake of 13,438 shares — an estimated $158K sold.

Point72 Asia (Singapore) first reported a position in INMB in Q1 2024 and held it in 1 quarter. The position peaked at $158K in Q1 2024. 57 funds tracked by Wall St. Rank hold INMB as of Q2 2024.

  • Point72 Asia (Singapore) reported no remaining INmune Bio position as of Q2 2024 after selling out during the quarter.
  • Point72 Asia (Singapore) sold 13,438 INmune Bio shares in Q2 2024, an estimated $158K.
  • Point72 Asia (Singapore) first reported a position in INmune Bio in Q1 2024 and held it in 1 quarter.
  • Point72 Asia (Singapore)'s INmune Bio position peaked at $158K in Q1 2024.
  • 57 funds tracked by Wall St. Rank held INmune Bio as of Q2 2024.

Based on Point72 Asia (Singapore)'s 13F filing for Q2 2024, filed 14 Aug 2024.